Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 265

1.

The Association of Mesalamine With Kidney Disease.

Adiga A, Goldfarb DS.

Adv Chronic Kidney Dis. 2020 Jan;27(1):72-76. doi: 10.1053/j.ackd.2019.09.002. Review.

PMID:
32147005
2.

Evaluation and medical management of patients with cystine nephrolithiasis: a consensus statement.

Eisner BH, Goldfarb DS, Baum M, Langman CB, Curhan GC, Preminger GM, Lieske J, Pareek G, Thomas K, Zisman A, Papagiannopoulos D, Sur R.

J Endourol. 2020 Feb 17. doi: 10.1089/end.2019.0703. [Epub ahead of print]

PMID:
32066273
3.

Vitamin D and Kidney Stones.

Schulster ML, Goldfarb DS.

Urology. 2020 Feb 4. pii: S0090-4295(20)30114-X. doi: 10.1016/j.urology.2020.01.030. [Epub ahead of print] Review.

PMID:
32032687
4.

Editorial: Uronephrology: a new nephrology subspecialty.

Goldfarb DS.

Curr Opin Nephrol Hypertens. 2020 Mar;29(2):199-200. doi: 10.1097/MNH.0000000000000589. No abstract available.

PMID:
31895164
5.

Occupational kidney stones.

Malieckal DA, Goldfarb DS.

Curr Opin Nephrol Hypertens. 2020 Mar;29(2):232-236. doi: 10.1097/MNH.0000000000000581.

PMID:
31895162
6.

Assessment of health-related quality of life in patients with cystinuria on tiopronin therapy.

Modersitzki F, Goldfarb DS, Goldstein RL, Sur RL, Penniston KL.

Urolithiasis. 2019 Dec 13. doi: 10.1007/s00240-019-01174-6. [Epub ahead of print]

PMID:
31834425
7.

Nephrolithiasis in women: how different from men?

Beara-Lasic L, Goldfarb DS.

Curr Opin Nephrol Hypertens. 2020 Mar;29(2):201-206. doi: 10.1097/MNH.0000000000000577.

PMID:
31789849
8.

Managing Hyperkalemia: Another Benefit of Exercise in People With Chronic Kidney Disease?

St-Jules DE, Marinaro M, Goldfarb DS, Byham-Gray LD, Wilund KR.

J Ren Nutr. 2019 Nov 22. pii: S1051-2276(19)30355-3. doi: 10.1053/j.jrn.2019.10.001. [Epub ahead of print] Review.

PMID:
31767517
9.

Medical evaluation of living kidney donors with nephrolithiasis: a survey of practices in the United States.

Tatapudi VS, Modersitzki F, Marineci S, Josephson MA, Goldfarb DS.

Clin Exp Nephrol. 2020 Mar;24(3):259-267. doi: 10.1007/s10157-019-01814-6. Epub 2019 Nov 6.

PMID:
31696378
10.

Access to Care for VA Dialysis Patients During Superstorm Sandy.

Lukowsky LR, Dobalian A, Goldfarb DS, Kalantar-Zadeh K, Der-Martirosian C.

J Prim Care Community Health. 2019 Jan-Dec;10:2150132719863599. doi: 10.1177/2150132719863599.

11.

Water to prevent kidney stones: tap vs bottled; soft vs hard - does it matter?

Willis S, Goldfarb DS, Thomas K, Bultitude M.

BJU Int. 2019 Dec;124(6):905-906. doi: 10.1111/bju.14871. Epub 2019 Aug 1. No abstract available.

PMID:
31310699
12.

Recurrent Calcium Kidney Stones.

Beara-Lasic L, Goldfarb DS.

Clin J Am Soc Nephrol. 2019 Sep 6;14(9):1388-1390. doi: 10.2215/CJN.02550319. Epub 2019 Jun 20. No abstract available.

PMID:
31221735
13.

The use of antibiotics and risk of kidney stones.

Joshi S, Goldfarb DS.

Curr Opin Nephrol Hypertens. 2019 Jul;28(4):311-315. doi: 10.1097/MNH.0000000000000510.

PMID:
31145705
14.

Effect of thiazolidinedione therapy on the risk of uric acid stones.

Asplin JR, Goldfarb DS.

Kidney Int. 2019 May;95(5):1022-1024. doi: 10.1016/j.kint.2019.02.003.

PMID:
31010476
15.

A Twin Study of Genetic Influences on Nephrolithiasis in Women and Men.

Goldfarb DS, Avery AR, Beara-Lasic L, Duncan GE, Goldberg J.

Kidney Int Rep. 2018 Nov 29;4(4):535-540. doi: 10.1016/j.ekir.2018.11.017. eCollection 2019 Apr.

16.

Effect of increasing doses of cystine-binding thiol drugs on cystine capacity in patients with cystinuria.

Malieckal DA, Modersitzki F, Mara K, Enders FT, Asplin JR, Goldfarb DS.

Urolithiasis. 2019 Dec;47(6):549-555. doi: 10.1007/s00240-019-01128-y. Epub 2019 Apr 13.

PMID:
30980122
17.

Sex differences in the temperature dependence of kidney stone presentations: a population-based aggregated case-crossover study.

Vicedo-Cabrera AM, Goldfarb DS, Kopp RE, Song L, Tasian GE.

Urolithiasis. 2020 Feb;48(1):37-46. doi: 10.1007/s00240-019-01129-x. Epub 2019 Mar 21.

PMID:
30900001
18.

Prevalence of low molecular weight proteinuria and Dent disease 1 CLCN5 mutations in proteinuric cohorts.

Beara-Lasic L, Cogal A, Mara K, Enders F, Mehta RA, Haskic Z, Furth SL, Trachtman H, Scheinman SJ, Milliner DS, Goldfarb DS, Harris PC, Lieske JC; investigators of the Rare Kidney Stone Consortium.

Pediatr Nephrol. 2020 Apr;35(4):633-640. doi: 10.1007/s00467-019-04210-0. Epub 2019 Mar 10.

PMID:
30852663
19.

Blood volume analysis as a guide for dry weight determination in chronic hemodialysis patients: a crossover study.

Malha L, Fattah H, Modersitzki F, Goldfarb DS.

BMC Nephrol. 2019 Feb 11;20(1):47. doi: 10.1186/s12882-019-1211-7.

20.

Editorial: Controversies in kidney stones and other chronic kidney disease topics.

Goldfarb DS.

Curr Opin Nephrol Hypertens. 2019 Mar;28(2):128-129. doi: 10.1097/MNH.0000000000000485. No abstract available.

21.

Differences in national and international guidelines regarding use of kidney stone formers as living kidney donors.

Tatapudi VS, Goldfarb DS.

Curr Opin Nephrol Hypertens. 2019 Mar;28(2):140-147. doi: 10.1097/MNH.0000000000000480. Review.

22.

Urine proteomic profiling in patients with nephrolithiasis and cystinuria.

Kovacevic L, Caruso JA, Lu H, Kovacevic N, Lakshmanan Y, Carruthers NJ, Goldfarb DS.

Int Urol Nephrol. 2019 Apr;51(4):593-599. doi: 10.1007/s11255-018-2044-1. Epub 2018 Dec 5.

23.

Cystinuria: genetic aspects, mouse models, and a new approach to therapy.

Sahota A, Tischfield JA, Goldfarb DS, Ward MD, Hu L.

Urolithiasis. 2019 Feb;47(1):57-66. doi: 10.1007/s00240-018-1101-7. Epub 2018 Dec 4. Review.

24.

Empiric therapy for kidney stones.

Goldfarb DS.

Urolithiasis. 2019 Feb;47(1):107-113. doi: 10.1007/s00240-018-1090-6. Epub 2018 Nov 26. Review.

25.

Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout.

Terkeltaub R, Saag KG, Goldfarb DS, Baumgartner S, Schechter BM, Valiyil R, Jalal D, Pillinger M, White WB.

Rheumatology (Oxford). 2019 Jan 1;58(1):61-69. doi: 10.1093/rheumatology/key245.

26.

Managing protein-energy wasting in hemodialysis patients: A comparison of animal- and plant-based protein foods.

St-Jules DE, Goldfarb DS, Popp CJ, Pompeii ML, Liebman SE.

Semin Dial. 2019 Jan;32(1):41-46. doi: 10.1111/sdi.12737. Epub 2018 Jul 15. Review.

PMID:
30009545
27.

Assessment and misassessment of potassium, phosphorus, and protein in the hemodialysis diet.

St-Jules DE, Goldfarb DS, Pompeii ML, Liebman SE, Sherman RA.

Semin Dial. 2018 Sep;31(5):479-486. doi: 10.1111/sdi.12713. Epub 2018 May 29. Review.

PMID:
29813179
28.

Oral Antibiotic Exposure and Kidney Stone Disease.

Tasian GE, Jemielita T, Goldfarb DS, Copelovitch L, Gerber JS, Wu Q, Denburg MR.

J Am Soc Nephrol. 2018 Jun;29(6):1731-1740. doi: 10.1681/ASN.2017111213. Epub 2018 May 10.

29.

Chronic pain in medullary sponge kidney: a rare and never described clinical presentation.

Gambaro G, Goldfarb DS, Baccaro R, Hirsch J, Topilow N, D'Alonzo S, Gambassi G, Ferraro PM.

J Nephrol. 2018 Aug;31(4):537-542. doi: 10.1007/s40620-018-0480-8. Epub 2018 Feb 21.

PMID:
29468561
30.

Tamm-Horsfall protein/uromodulin deficiency elicits tubular compensatory responses leading to hypertension and hyperuricemia.

Liu Y, Goldfarb DS, El-Achkar TM, Lieske JC, Wu XR.

Am J Physiol Renal Physiol. 2018 Jun 1;314(6):F1062-F1076. doi: 10.1152/ajprenal.00233.2017. Epub 2018 Jan 10.

31.

Assessment of the combination of temperature and relative humidity on kidney stone presentations.

Ross ME, Vicedo-Cabrera AM, Kopp RE, Song L, Goldfarb DS, Pulido J, Warner S, Furth SL, Tasian GE.

Environ Res. 2018 Apr;162:97-105. doi: 10.1016/j.envres.2017.12.020. Epub 2017 Dec 28.

32.

Comparison of the effect of allopurinol and febuxostat on urinary 2,8-dihydroxyadenine excretion in patients with Adenine phosphoribosyltransferase deficiency (APRTd): A clinical trial.

Edvardsson VO, Runolfsdottir HL, Thorsteinsdottir UA, Sch Agustsdottir IM, Oddsdottir GS, Eiriksson F, Goldfarb DS, Thorsteinsdottir M, Palsson R.

Eur J Intern Med. 2018 Feb;48:75-79. doi: 10.1016/j.ejim.2017.10.007. Epub 2017 Dec 12.

33.

Case Study - Case Studies in Cystinuria.

Goldfarb DS, Grasso M.

Urol Nurs. 2017 Mar-Apr;37(2):90-3.

34.

Early Recognition and Management of Rare Kidney Stone Disorders.

Goldstein B, Goldfarb DS.

Urol Nurs. 2017 Mar-Apr;37(2):81-9, 102.

35.

Meeting the Needs of the Complex Older Adult Patient with Urinary Retention: A Case Study.

Goldstein B, Goldfarb DS.

Urol Nurs. 2017 Mar-Apr;37(2):75-80.

PMID:
29240371
36.

Personalized Intervention in Monogenic Stone Formers.

Policastro LJ, Saggi SJ, Goldfarb DS, Weiss JP.

J Urol. 2018 Mar;199(3):623-632. doi: 10.1016/j.juro.2017.09.143. Epub 2017 Oct 20. Review.

37.

The Healthy Hearts and Kidneys (HHK) study: Design of a 2×2 RCT of technology-supported self-monitoring and social cognitive theory-based counseling to engage overweight people with diabetes and chronic kidney disease in multiple lifestyle changes.

Sevick MA, Woolf K, Mattoo A, Katz SD, Li H, St-Jules DE, Jagannathan R, Hu L, Pompeii ML, Ganguzza L, Li Z, Sierra A, Williams SK, Goldfarb DS.

Contemp Clin Trials. 2018 Jan;64:265-273. doi: 10.1016/j.cct.2017.08.020. Epub 2017 Sep 1.

38.

Refining Diagnostic Approaches in Nephrolithiasis: Incomplete Distal Renal Tubular Acidosis.

Goldfarb DS.

Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1380-1382. doi: 10.2215/CJN.07160717. Epub 2017 Aug 3. No abstract available.

39.

Phosphate Additive Avoidance in Chronic Kidney Disease.

St-Jules DE, Goldfarb DS, Pompeii ML, Sevick MA.

Diabetes Spectr. 2017 May;30(2):101-106. doi: 10.2337/ds16-0048.

40.

Opioid Overuse or NSAID Underuse? A Response to the Pain Guide.

Hiremath S, Goldfarb DS, Juurlink DN.

Am J Kidney Dis. 2017 Jun;69(6):865. doi: 10.1053/j.ajkd.2017.02.375. Epub 2017 Apr 25. No abstract available.

PMID:
28454686
41.

Renal Replacement Therapy and Incremental Hemodialysis for Veterans with Advanced Chronic Kidney Disease.

Kalantar-Zadeh K, Crowley ST, Beddhu S, Chen JLT, Daugirdas JT, Goldfarb DS, Jin A, Kovesdy CP, Leehey DJ, Moradi H, Navaneethan SD, Norris KC, Obi Y, O'Hare A, Shafi T, Streja E, Unruh ML, Vachharajani TJ, Weisbord S, Rhee CM.

Semin Dial. 2017 May;30(3):251-261. doi: 10.1111/sdi.12601. Epub 2017 Apr 18. Review.

42.

Effects of an unusual poison identify a lifespan role for Topoisomerase 2 in Saccharomyces cerevisiae.

Tombline G, Millen JI, Polevoda B, Rapaport M, Baxter B, Van Meter M, Gilbertson M, Madrey J, Piazza GA, Rasmussen L, Wennerberg K, White EL, Nitiss JL, Goldfarb DS.

Aging (Albany NY). 2017 Jan 5;9(1):68-97. doi: 10.18632/aging.101114.

43.

The role of the microbiome in kidney stone formation.

Mehta M, Goldfarb DS, Nazzal L.

Int J Surg. 2016 Dec;36(Pt D):607-612. doi: 10.1016/j.ijsu.2016.11.024. Epub 2016 Nov 12. Review.

44.

Does Vitamin D Supplementation Cause Kidney Stones?

Goldfarb DS.

J Urol. 2017 Feb;197(2):280-281. doi: 10.1016/j.juro.2016.11.072. Epub 2016 Nov 11. No abstract available.

PMID:
27845148
45.

Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement.

Gambaro G, Croppi E, Coe F, Lingeman J, Moe O, Worcester E, Buchholz N, Bushinsky D, Curhan GC, Ferraro PM, Fuster D, Goldfarb DS, Heilberg IP, Hess B, Lieske J, Marangella M, Milliner D, Preminger GM, Reis Santos JM, Sakhaee K, Sarica K, Siener R, Strazzullo P, Williams JC; Consensus Conference Group.

J Nephrol. 2016 Dec;29(6):715-734. Epub 2016 Jul 25. Review.

46.

The Role of the 24-Hour Urine Collection in the Prevention of Kidney Stone Recurrence.

Hsi RS, Sanford T, Goldfarb DS, Stoller ML.

J Urol. 2017 Apr;197(4):1084-1089. doi: 10.1016/j.juro.2016.10.052. Epub 2016 Oct 13. Review.

47.

l-Cystine Diamides as l-Cystine Crystallization Inhibitors for Cystinuria.

Hu L, Yang Y, Aloysius H, Albanyan H, Yang M, Liang JJ, Yu A, Shtukenberg A, Poloni LN, Kholodovych V, Tischfield JA, Goldfarb DS, Ward MD, Sahota A.

J Med Chem. 2016 Aug 11;59(15):7293-8. doi: 10.1021/acs.jmedchem.6b00647. Epub 2016 Jul 26.

48.

A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.

Laskowski LK, Goldfarb DS, Howland MA, Kavcsak K, Lugassy DM, Smith SW.

J Med Toxicol. 2016 Sep;12(3):305-8. doi: 10.1007/s13181-016-0543-y. Epub 2016 Mar 17.

49.

Nutrient Non-equivalence: Does Restricting High-Potassium Plant Foods Help to Prevent Hyperkalemia in Hemodialysis Patients?

St-Jules DE, Goldfarb DS, Sevick MA.

J Ren Nutr. 2016 Sep;26(5):282-7. doi: 10.1053/j.jrn.2016.02.005. Epub 2016 Mar 12. Review. Erratum in: J Ren Nutr. 2016 Nov;26(6):416.

50.

Urinary Stone Disease: Advancing Knowledge, Patient Care, and Population Health.

Scales CD Jr, Tasian GE, Schwaderer AL, Goldfarb DS, Star RA, Kirkali Z.

Clin J Am Soc Nephrol. 2016 Jul 7;11(7):1305-12. doi: 10.2215/CJN.13251215. Epub 2016 Mar 10. Review.

Supplemental Content

Loading ...
Support Center